What It Is
DSIP, or delta sleep-inducing peptide, is a nine-amino-acid peptide first reported in 1977 after experiments involving rabbit cerebral venous blood and delta-wave EEG activity.[2] FDA uses the name emideltide for the same reported sequence and distinguishes its free-base and acetate forms as separate bulk substances.[19] Older reviewers also cautioned that some "DSIP-like immunoreactivity" may reflect related fragments rather than intact peptide.[3]
Despite its name, DSIP is not an established sleep medication. Its clinical literature is small, old, formulation-ambiguous, and methodologically limited.
How It Works
Human sleep is regulated by a distributed network spanning the hypothalamus, brainstem, thalamus, and cortex, and by two interacting processes: a circadian clock and a homeostatic drive that builds with time spent awake.[9][11] DSIP has been discussed within this broader framework, but no single receptor or validated mechanism has been identified that clearly explains its reported effects.[3]
This is a meaningful gap compared with approved sleep medications, most of which act on well-characterized receptor systems. A plausible biological link to sleep-wake circuitry is not the same as a demonstrated clinical mechanism.
What the Research Shows
The original evidence comes from rabbit and rat experiments examining EEG and sleep-stage changes.[2] Small human studies followed, but FDA's 2026 review found the insomnia results inconclusive and preliminary: some tiny intravenous studies reported sleep changes, while other double-blind placebo-controlled studies found no significant objective or subjective benefit.[19]
FDA found no data supporting the nominated subcutaneous route for chronic insomnia, narcolepsy, or opioid withdrawal, and current clinical guidelines do not discuss emideltide for those conditions.[19] Claims about lucid dreaming or a standard sleep-enhancement regimen are unsupported.
Safety & Side Effects
DSIP/emideltide has no FDA-approved label or modern safety database. FDA identified limited intravenous exposure in small older studies but no safety data for the nominated subcutaneous route. Withdrawal studies reported transient headache, nausea, vertigo, and cases of progressive hypotension after a second intravenous injection.[19]
Long-term toxicity, reproductive safety, carcinogenicity, interactions, and the consequences of inconsistent identity between free-base and acetate products remain unresolved. Combining an unapproved sleep-related compound with alcohol, sedatives, or other central-nervous-system depressants would have unknown risk.
Regulatory Status
DSIP/emideltide is not an approved medication in Drugs@FDA or the Orange Book and has no FDA-approved indication, formulation, route, or dose.[4][5] At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA evaluated emideltide free base and acetate for insomnia, narcolepsy, and opioid withdrawal.[18]
FDA's briefing proposed not adding either substance to the 503A Bulks List because of poor characterization, insufficient safety information, and lack of adequate effectiveness evidence.[19] The proposal is advisory-process context, not an approval; FDA's current risk page separately lists emideltide among bulk substances that may present significant safety risks.[20]
How DSIP Compares to Approved Sleep Aids
Evidence-based insomnia care typically starts with behavioral treatment, such as cognitive behavioral therapy for insomnia, and, when appropriate, FDA-approved medications with defined indications, dosing, and safety monitoring.[13] DSIP has none of that infrastructure: no approved indication, no standard dose, and no modern trial program comparable to what supports approved hypnotics.
Even melatonin, a widely available over-the-counter supplement discussed for circadian sleep timing, has a more developed modern evidence base than DSIP does for insomnia.[15] DSIP remains best characterized as a historically interesting research peptide rather than a validated alternative to established sleep treatments.